-
Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee
04 Sep 2025 11:00 GMT
… its portfolio of innovative cancer medicines and was acquired … at Novartis Pharmaceuticals and as a Senior Pharmaceutical Representative … commercialization of transformative treatments and Michael’s … trials.” “At a time when many early stage biotechnology …
-
Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy
02 Sep 2025 20:41 GMT
… of the CML landscape, CancerNetwork® spoke with Jorge Cortes, … generation—dasatinib [Sprycel], nilotinib [Tasigna], and a bit later, … able to give them their leukemia treatment. We need to do … Drug Evaluation and Research: Application Number: NDA 21-335. FDA. …
-
April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
29 Aug 2025 20:22 GMT
… include information about osteonecrosis.
Tasigna labeling
FDA determined that Gleevec and Sprycel … Warnings and Precautions", "Drug Interactions", and " … zoster.
Sarclisa labeling
Sprycel (dasatinib)
Drug-induced liver injury
The “Warnings …
-
Gastrointestinal Stromal Tumors Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, And Companies
21 Aug 2025 00:37 GMT
… trial specifically excludes individuals with advanced non-small cell lung cancer … Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals … myelogenous leukemia … Treatment Drugs
Gastrointestinal Stromal Tumors Companies
Jiangsu Hengrui Medicine …
-
Liberia: Patients at CB Dunbar Hospital Praise Direct Relief for Free Lifesaving Drugs
13 Jun 2025 04:46 GMT
… told us the drug is only … leukemia patients are currently receiving treatment at CB Dunbar Hospital using medications … such as Imatinib (Glivec), Nilotinib (Tasigna … better,” a medical doctor at the hospital …
-
Dr Swoboda on the Role of TKIs in Chronic Myeloid Leukemia
31 May 2025 02:11 GMT
… Cancer Institute, discussed the roles of available TKIs for the treatment … of patients with chronic myeloid leukemia (CML).
Since … TKIs subsequently received FDA approval: dasatinib (Sprycel), nilotinib (Tasigna), and bosutinib ( …
-
Pharmacokinetic profile of novel reduced-dose Danziten (nilotinib tablets) versus Tasigna (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis.
12 May 2025 10:36 GMT
… PK approach, establish bioequivalence vs. Tasigna (nilotinib capsules) and investigate food … twice daily dosing with various treatment and food conditions were simulated …
-
Rutgers Cancer Institute Reviews Guidelines for Managing Blood Cancers During Pregnancy
09 Apr 2025 00:54 GMT
… researchers at Rutgers Cancer Institute Department of Blood … in maternal-fetal medicine. Any treatment decisions should be … along with Rituxan.
Treatment of leukemia during pregnancy varies … Phyrago or Sprycel (dasatinib), Tasigna or Danziten (nilotinib), and …
-
FDA Approves Scemblix for Some With Newly Diagnosed Chronic Myeloid Leukemia
29 Oct 2024 19:05 GMT
… Food and Drug Administration (FDA) for the treatment of adults … kinase inhibitor, which included Tasigna (nilotinib), Gleevec (imatinib), … from the ASC4FIRST trial were presented at … treatment paradigm in [chronic myeloid leukemia].”
For more news on cancer …
-
Addressing Treatment Gaps in High-Risk CML in Blast Phase
05 Apr 2025 02:47 GMT
… Medical Oncology, Cleveland Clinic, critical gaps exist in blast-phase treatment … leukemia have a life expectancy of normal individuals or people without cancer … treatment—and multiple newer TKIs in clinical trials … TKIs—nilotinib [Tasigna], dasatinib [Sprycel …
About
© 1995-2025